Zynerba Pharmaceuticals Return on Equity

Zynerba Pharmaceuticals (ZYNE) currently reports a ROE of -127.53%. That is below the Healthcare sector average of 21.67%. Use the charts on this page to explore Zynerba Pharmaceuticals's ROE history and peer comparisons.

Zynerba Pharmaceuticals's ROE of -127.53% is lower than the Healthcare sector average of 21.67%. That is roughly 688.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Zynerba Pharmaceuticals's current -127.53% should be judged against Healthcare norms (sector average: 21.67%) and against ZYNE's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -127.53%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.67%. From there, open related valuation or income-statement pages for Zynerba Pharmaceuticals, and consider following ZYNE for alerts when major investors trade the stock.

Zynerba Pharmaceuticals is classified in the Healthcare sector. On ROE, it currently shows -127.53% versus a sector average near 21.67%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ZYNE with unrelated industries.